Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.61 |
| ▸ | TDO2 | P48775 | 12/20 | 0.61 |
| ▸ | NOS1 | P29475 | 4/20 | 0.50 |
| ▸ | METAP2 | P50579 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410369 | 1.00 | IDO1 (0.61) | IDO1TDO2NOS1METAP2DYRK1A | |
| SCHEMBL14487466 | 0.79 | METAP2 (0.56) | IDO1TDO2NOS1METAP2DYRK1A | |
| SCHEMBL17875686 | 0.79 | TDO2 (0.66) | IDO1TDO2NOS1METAP2DYRK1A | |
| SCHEMBL1118862 | 0.76 | TDO2 (1.00) | IDO1TDO2NOS1METAP2DYRK1A | |
| SCHEMBL22499161 | 0.76 | TDO2 (0.61) | IDO1TDO2NOS1METAP2DYRK1A | |
| SCHEMBL31190826 | 0.76 | METAP2 (0.53) | IDO1TDO2NOS1METAP2DYRK1A | |
| SCHEMBL7572191 | 0.76 | NOS1 (0.50) | IDO1TDO2NOS1METAP2DYRK1A | |
| SCHEMBL1709837 | 0.76 | IDO1 (0.61) | IDO1TDO2NOS1METAP2DYRK1A | |
| SCHEMBL1318814 | 0.76 | TDO2 (0.61) | IDO1TDO2NOS1METAP2DYRK1A | |
| SCHEMBL29920973 | 0.76 | TDO2 (1.00) | IDO1TDO2NOS1METAP2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111995577-A | Synthetic method of 4-fluoro indazole 3-carbonitrile or derivatives thereof | 上海代为化学科技有限公司 | 2020-11-27 | — | — | CN | claimed |
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | disclosed |
| CN-122055363-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4724438-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4003977-B1 | PYRIDINE DERIVATIVES AS CALCIUM-ACTIVATED CHLORIDE CHANNEL MODULATORS | TMEM16A LTD (GB) | 2026-04-15 | — | — | EP | disclosed |
| EP-4716532-A2 | BICYCLIC HETEROARYL COMPOUNDS | Quantx Biosciences US, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12545658-B2 | Pyridine derivatives as calcium-activated chloride channel modulators | TMEM16A LIMITED (GB) | 2026-02-10 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | US | disclosed |
| WO-2019027960-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019027960-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-3055300-B1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| US-9278953-B2 | Antagonists of prostaglandin EP3 receptor | PFIZER INC. (US) | 2016-03-08 | — | — | US | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | CTTN, SRC, PTK2 | IDO1 3020/4885TDO2 2317/4885NOS1 4286/4885 |
| US-12545658-B2 | Pyridine derivatives as calcium-activated chloride channel modulators | CACNA1E, CACNA1D, CACNA1B | IDO1 3978/4885TDO2 4383/4885NOS1 2090/4885 |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | IDO1 566/4885TDO2 1694/4885NOS1 1230/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | IDO1 1123/4885TDO2 1283/4885NOS1 2090/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | IDO1 1216/4885TDO2 1863/4885NOS1 879/4885 |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | IDO1 2532/4885TDO2 4666/4885NOS1 3438/4885 |
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PTGER3, PTGES3, PTGER2 | IDO1 2606/4885TDO2 3660/4885NOS1 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.